Novalgin (Metamizole Sodium Monohydrate)

Metamizole works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production involved in pain and fever pathways. It also modulates central nervous system pain transmission, providing both peripheral and central analgesic effects that help control various types of acute and visceral pain.

The appropriate dose of Novalgin is determined by the prescribing clinician based on the patient’s age, weight, severity of pain or fever, and overall health status. Dosage regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

Safety of Novalgin in pregnancy or lactation has not been definitively established. It should only be used if the potential therapeutic benefit justifies the possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To order Novalgin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Novalgin (metamizole) belongs to the pyrazolone class, offering analgesic and antipyretic effects similar to NSAIDs but with a distinct mechanism that includes central pain modulation. It may be preferred when NSAIDs are contraindicated, though it carries a unique risk profile, including rare blood‑cell disorders.

Novalgin should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Novalgin is administered orally, typically in tablet or liquid form, as directed by a healthcare professional. The medication should be taken with a full glass of water and may be taken with or without food, depending on the prescriber’s guidance.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, skin changes, or breathing difficulties, and seek immediate medical attention if these occur.

Novalgin should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, patients with a history of agranulocytosis, severe liver or kidney impairment, and those taking medications that may interact dangerously, such as certain anticoagulants, without close medical supervision.